Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off : efficacy, safety and feasibility--an open-label, 6-week study

Eggert, Karla ; Skogar, Orjan LU orcid ; Amar, Khaled ; Luotonen, Liisa ; Kuoppamäki, Mikko ; Leinonen, Mika ; Nissinen, Helena and Oertel, Wolfgang (2010) In Journal of Neural Transmission 117(3). p.333-342
Abstract

The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change... (More)

The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change or worsening'). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Aged, Antiparkinson Agents/administration & dosage, Benserazide/administration & dosage, Carbidopa/administration & dosage, Catechols/administration & dosage, Drug-Related Side Effects and Adverse Reactions, Dyskinesias/drug therapy, Feasibility Studies, Female, Humans, Levodopa/administration & dosage, Male, Nitriles/administration & dosage, Parkinson Disease/drug therapy, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome
in
Journal of Neural Transmission
volume
117
issue
3
pages
333 - 342
publisher
Springer
external identifiers
  • scopus:77952430396
  • pmid:20013007
ISSN
0300-9564
DOI
10.1007/s00702-009-0344-4
language
English
LU publication?
no
id
a1799725-b78a-41c3-8c9d-7d343e14358e
date added to LUP
2024-05-08 15:06:06
date last changed
2024-06-06 11:57:57
@article{a1799725-b78a-41c3-8c9d-7d343e14358e,
  abstract     = {{<p>The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p &lt; 0.0001 vs. patients reporting 'no change or worsening'). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.</p>}},
  author       = {{Eggert, Karla and Skogar, Orjan and Amar, Khaled and Luotonen, Liisa and Kuoppamäki, Mikko and Leinonen, Mika and Nissinen, Helena and Oertel, Wolfgang}},
  issn         = {{0300-9564}},
  keywords     = {{Aged; Antiparkinson Agents/administration & dosage; Benserazide/administration & dosage; Carbidopa/administration & dosage; Catechols/administration & dosage; Drug-Related Side Effects and Adverse Reactions; Dyskinesias/drug therapy; Feasibility Studies; Female; Humans; Levodopa/administration & dosage; Male; Nitriles/administration & dosage; Parkinson Disease/drug therapy; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{333--342}},
  publisher    = {{Springer}},
  series       = {{Journal of Neural Transmission}},
  title        = {{Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off : efficacy, safety and feasibility--an open-label, 6-week study}},
  url          = {{http://dx.doi.org/10.1007/s00702-009-0344-4}},
  doi          = {{10.1007/s00702-009-0344-4}},
  volume       = {{117}},
  year         = {{2010}},
}